Ionis Pharmaceuticals (IONS) Competitors $31.50 +0.79 (+2.57%) As of 02:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Which has more volatility & risk, BIIB or IONS? Biogen has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Which has stronger earnings & valuation, BIIB or IONS? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B1.83$1.63B$11.1910.82Ionis Pharmaceuticals$705.14M6.92-$366.29M-$3.04-10.10 Do insiders and institutionals hold more shares of BIIB or IONS? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer BIIB or IONS? In the previous week, Biogen had 30 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 50 mentions for Biogen and 20 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.17 beat Biogen's score of 0.57 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 22 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in BIIB or IONS? Biogen received 1114 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 71.31% of users gave Biogen an outperform vote while only 60.36% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes181971.31% Underperform Votes73228.69% Ionis PharmaceuticalsOutperform Votes70560.36% Underperform Votes46339.64% Do analysts recommend BIIB or IONS? Biogen presently has a consensus target price of $201.93, suggesting a potential upside of 66.77%. Ionis Pharmaceuticals has a consensus target price of $56.44, suggesting a potential upside of 83.80%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.70 Is BIIB or IONS more profitable? Biogen has a net margin of 16.87% compared to Ionis Pharmaceuticals' net margin of -64.25%. Biogen's return on equity of 14.98% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.87% 14.98% 8.76% Ionis Pharmaceuticals -64.25%-100.05%-15.70% SummaryBiogen beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.88B$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-10.107.4422.5118.48Price / Sales6.92242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book8.306.516.774.25Net Income-$366.29M$143.21M$3.22B$248.23M7 Day Performance3.86%1.98%1.45%0.89%1 Month Performance12.66%6.89%3.97%3.53%1 Year Performance-28.60%-2.52%16.14%5.08% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals4.271 of 5 stars$31.50+2.6%$56.67+79.9%-25.6%$5.01B$705.14M-10.37800Earnings ReportAnalyst ForecastNews CoverageBIIBBiogen4.6945 of 5 stars$116.49-1.8%$213.15+83.0%-43.6%$17.05B$9.68B10.418,720Earnings ReportAnalyst DowngradeAnalyst RevisionNews CoverageUTHRUnited Therapeutics4.9809 of 5 stars$284.25-0.2%$395.67+39.2%+29.3%$12.77B$2.88B12.48980Earnings ReportAnalyst RevisionNews CoveragePositive NewsBMRNBioMarin Pharmaceutical4.9305 of 5 stars$58.65-0.9%$94.00+60.3%-21.1%$11.19B$2.85B26.663,080Positive NewsINCYIncyte4.7149 of 5 stars$56.80-2.4%$74.69+31.5%+20.4%$10.99B$4.24B210.382,320Earnings ReportAnalyst ForecastNBIXNeurocrine Biosciences4.8738 of 5 stars$100.68-0.7%$161.86+60.8%-21.7%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXELExelixis4.076 of 5 stars$35.59-1.7%$37.59+5.6%+66.9%$9.96B$2.17B20.111,220Short Interest ↑Analyst RevisionPositive NewsEXASExact Sciences4.4898 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400RGENRepligen4.8597 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoverageHALOHalozyme Therapeutics4.0007 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionNews CoverageMDGLMadrigal Pharmaceuticals3.7511 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690Earnings ReportNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors HALO Competitors MDGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IONS Stock Free IONS Stock Alerts